BioSculpture Technology, Inc. is a spinoff of Rocin Laboratories, Inc. and the exclusive licensee of its tissue aspiration and processing portfolio. It was created when the overwhelming success of the licensing program of the Lipotome(TM) Sales Division suggested that an independent company be created to exclusively license the parent company’s tissue aspiration platform and patent portfolio to expedite the development and introduction of more advanced designs into the operating room.
At BioSculpture Tech., we pioneer transformative solutions for health and body challenges, empowering surgeons with cutting-edge innovations. Our focus extends beyond minimally invasive fat removal to advancing laparoscopic techniques for visceral fat reduction, offering the potential for significant metabolic improvement and sustainable weight loss.
We are dedicated to enhancing patient experiences through faster recovery times, reduced healthcare costs, improved accessibility, and proactive treatment of metabolic syndrome and type 2 diabetes. By addressing these conditions early, we strive to extend and improve lives while contributing to a more efficient healthcare system.
We focus not only on minimally invasive fat removal devices that release the artist of the surgeon® performing cosmetic liposuction but ones that will facilitate the laparoscopic removal of visceral fat with potential of achieving significant metabolic improvement and subsequent weight loss. We wish to provide better patient experiences, shorter convalescences, lower cost of care, improved access, and earlier treatment of metabolic syndrome and type 2 diabetes. We believe that tackling metabolic syndrome as early as possible can significantly lengthen and improve patient’s lives and reduce healthcare costs.
Our corporate mission is to unleash the artist in the surgeon® for cosmetic procedures, develop innovative solutions based on science(TM) for treatment applications, and be a world leading manufacturer and developer of medical devices and procedures for handling adipose tissue targeting the liposuction and body sculpting market, the bariatric treatment market, and the fat autograft and adipocyte-derived stem cell processing markets.
We believe that the best way to serve physicians, the patients they treat, and our shareholders is to improve the surgical experience with reliable, safe and affordable instruments which make surgery a more controlled, predictable and less painful experience. And then to stand behind those instruments and respond to needs and requests of our customers to continue to improve and evolve with them.
In the words of our President, Robert L. Cucin, M.D., “We seek to maintain a standard of uncompromising quality, foster an environment of integrity and respect, and transform every stumbling block to innovation into a building block for progress.”
BioSculpture Technology, Inc. specializes in the advanced power assisted dual-cannula tissue aspiration systems which allow controlled and effortless tissue removal. These tube-within-a-tube Twin Cannula Assisted Liposuction or “TCAL” power assisted liposuction systems offer dramatic advantages in control and reduced effort over less sophisticated methods, even single cannula Power Assisted Liposuction or “PAL” systems, a technology BST’s founder also invented. TCAL can be safely adapted for other specialties and uses for which manual and other powered systems would pose a hazard. BST believes endoscopic and laparoscopic applications in particular have high potential for generating significant future revenue streams.
Surgeons using our instruments for the first time have described them as “revolutionary” or “evolutionary.” It is almost impossible to get a physician to surrender the instrument being tested to complete the rest of his procedure manually. The most frequent question asked by the testing physician is, “How soon can I have it?